Efficacy of glucosamine plus diacerein versus monotherapy of glucosamine: a double-blind, parallel randomized clinical trial

Table 2 VAS scores, WOMAC total scores, WOMAC subscores, and joint space width at 6-month follow-up

Outcome at last follow-up	Treatment		Mean differences between groups	95 % CI	P value
Outcome at last follow-up	Glucosamine plus diacerein	Glucosamine plus placebo	Mean differences between groups	95 % CI	P value
VAS score	2.97 (2.38–3.56)	2.88 (2.29–3.47)	0.09	−0.75, 0.94	0.710
WOMAC scores
Total	48.59 (38.30–58.89)	48.69 (38.34–59.05)	−0.10	−14.95, 14.75	0.990
Pain	12.02 (9.53–14.52)	11.76 (9.25–14.27)	0.26	−3.34, 3.86	0.887
Stiffness	3.85 (2.79–4.91)	4.16 (3.07–5.26)	−0.32	−1.87, 1.24	0.687
Function	32.74 (25.70–39.79)	32.74 (25.66–39.82)	0.01	−10.15, 10.16	0.999
JSW, mm	2.63 (2.41–2.84)	2.59 (2.37–2.81)	0.04	−0.35, 0.27	0.803

Abbreviations: JSW Joint space width, VAS Visual analogue scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index

ISSN: 1478-6362